Diuretic agent

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a diuretic of the aquaretic group that is 4-nitro-phenyl-O-D-glucopyranoside. The agent may be used both to treat greater and lesser circulation congestions caused by cardiac failure, and to intensify water release thereby helping to reduce oedemas. The diuretic agent has high and low saluretic activity unlike the existing diuretics and expands the range of products of synthetic origin possessing diuretic activity.

EFFECT: agent is applicable for treating a number of cardiovascular diseases accompanied by excessive hydration and developing oedema syndrome.

1 tbl


The invention relates to pharmacology, namely a drug with diuretic group of aquaretto, and can be used to treat nephritis, pielonefritom, cystitis, hypertension, symptomatic hypertension, diseases, accompanied by the development of edema syndrome, as this substance increases the excretion of water, thereby reducing the swelling.

Currently, there is a need to develop diuretics, high diuretic activity and low toxicity. Of particular interest is the creation of medicines, which has diuretic and does not affect the allocation of kidneys ions of sodium, potassium, magnesium.

It is known tool that has a diuretic effect, namely, ethacrynic acid, which is used as a selective antagonist of sodium-potassium-glastransporter (NKCC).

The disadvantage etakrinova acid is the high toxicity and the absence of diuretic action in animals, for example, in rats.(Bryukhanov V.M., Zverev AF Side effects of modern diuretics: Metabolic and toxic-allergic aspects of Novosibirsk.: CARES, 2003. - 224 S.).

The closest to the achieved result is a tool that has diuretic de is predetermined, namely furosemide.

Lack of furosemide in the first place is salureticheskoe activity. Like all loop diuretics, furosemide inhibits the reabsorption in the renal reabsorption of sodium, potassium and chloride. In addition, furosemide causes such metabolic disorders as hypokalemia, gipohloremicski alkalosis, hyperglycemia, hyperuricemia (Zverev AF, Bryukhanov V.M. Pharmacology and clinical use extrarenal action of diuretics - M: Medical book, 2000. - 256 S.).

The technical result of the proposed drug is the expansion of the means of possessing diuretic activity of synthetic origin.

The technical result is achieved by using 4-nitro-phenyl-O-D-glucopyranoside as a means possessing diuretic properties.

Description of the invention

The inventive tool is a 4-nitro-phenyl-o-O-glucopyranosid the following formula:

The glycoside was obtained using acetobromogalactose in aqueous acetone. The structure was proved by NMR. Acyl protection was removed with sodium methylate. Preparative output: 10,3%.

The proposed tool was prepared as follows: To 0,0012 mol (20% excess relative to p-NITROPHENOL) acetobromogalactose dissolved in 5 ml of acetone. Then add 0.001 mol p-NITROPHENOL is equimolar amount of 1.1 N. Mahon. Leave the reaction mass for 24 hours at room temperature. Then they drive off the acetone under vacuum. The extraction is carried out CHCl3(3×20 ml), washed with 20 ml of 1,1 N. lye. The chloroform solution is dried over calcium chloride. After which the chloroform is distilled off. The oily residue is crystallized from ethyl alcohol. Crystals of 4-nitrophenyl-2,3,4,6-Tetra-O-β-acetyl-D-glucopyranoside filtered.

To a suspension containing 2 g of 4-nitrophenyl-2,3,4,6-Tetra-D-β-acetyl-D-glucopyranoside in 5 ml of absolute methanol, add 0.5 ml of 2 n solution of sodium methylate, the mixture shaken until complete dissolution of the precipitate, then leave at 5 (by 18 hours After 15-20 min is the selection. The solvent is distilled off, the residue is recrystallized from methanol. Yield: 16%.

The NMR spectra of the proposed drug:

An NMR spectrum1H (D2O), δ, ppm: 3.42-3.70 (5H, m, H-2', H-3', H-4', H-5', H-6'b); 3.84 (1H, d, H-6'a, J=12.0 Hz); 5.1 (1H, m, H-1'); 7.13 (2H, d, J=8.1 Hz, H-2, H-6); 8.14 (2H, d, H-3, H-5, J=8.4 Hz).

An NMR spectrum13(D2O), δ, ppm: 60.4 (CH2, C6'); 69.3 (CH, C-4'); 72.7 (CH, C-2'); 75.5 (CH, C-5'), 76,2 (CH, C-3'); 99.4(CH, C-1'); 116.4 (2×CH, C-2, C-6); 126.0 (2×CH, C-3, C-5); 142.42(S, C-4); 161.7 (s, s-1).

The NMR spectra of1H,13With were recorded on FTIR spectrometer Bruker Avante-300 (300 MHz), Bruker (Germany) internal standard HMDS, as dissolve what I used deuterated acetone. The melting point was determined on microsegregation table Boetius of the company Boetius (Germany).

The resulting tool is characterized by the following properties:

white crystals. Soluble in water, alcohol, chloroform.

Pharmacological action the proposed drug tested by biological research. Activity funds were estimated at 12 laboratory rats-females weighing 200-220 grams. In the beginning of the experiment were determined baseline urine output, as well as the content of sodium and potassium in the urine of experimental animals. The concentration of ions in the urine were determined by flame photometry on the analyzer the FCA-2-01 (Russia). The analyte was injected to rats intragastrically for seven days at a dose of 54 µmol/kg Daily in experimental animals was measured volume of allocated urine. The experimental results were processed by the statistical method using the criterion of Mann-Whitney. The difference compared averages were considered significant if the confidence value (P) was less than 0.05.

The table presents comparative characteristics of diuretic activity of 4-nitro-phenyl-O-D-glucopyranoside. Diuretic activity of 4-nitro-phenyl-O-D-glucopyranoside at a dose of 54 µmol/kg

As can be seen from table 1, the introduction of the compounds according to the invention increased daily diuresis 1.5 andmore times compared with the control. Excretion of sodium and potassium ions under the influence of the compounds according to the invention is significantly decreased starting from the 3rd day of the experiment.

Thus, the claimed product has a pronounced diuretic activity and is applicable for treatment of stagnant phenomena in small and large circle circulation caused by congestive heart failure, nephritis, cirrhosis of the liver with symptoms of portal hypertension, hypertension, symptomatic hypertension, glaucoma and other diseases associated with development of edema syndrome.

Table 1.
A means with diuretic
The day of introduction of the analyte of interestIndicators of kidney function
Daily diuresisThe excretion of sodiumExcretion of potassium
1 day3,93±0,53*33,33±10,44618,33±69,25
day 2to 4.38±0,54*
3 day4,34±0,55*9,49±1,59321,67±41,14*
day 4of 4.44±0,51*
5 day3,84±0,719,19±2,00*315,53±49,54*
day 63,76±0,70--------
day 7 5,17±0,68*of 7.96±0,83398,99±33,68
Note. The asterisk is a difference significantly compared to control.

The use of 4-nitro-phenyl-O-D-glucopyranoside of the formula

as a means possessing diuretic.


Same patents:

FIELD: medicine.

SUBSTANCE: what is described is a new pharmaceutically solid preparation of a vasopressin antagonist which contains: (a) 7-chlor-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro- 1H-benzoazepine and/or its salt; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in the amount of 50% or more; and (c) at least one of the ingredients specified in a group consisting of carmellose, sodium carboxymethyl starch, crospovidone and hydroxypropylcellulose with a lower degree of substitution with an average diameter of particles 30 to 70 mcm and 90% of the cumulative diameter of 100 to 200 mcm.

EFFECT: pharmaceutical solid preparation shows excellent desintegration properties and solubility leading to adequate gastrointestinal absorbability of the active ingredients.

17 cl, 4 tbl, 21 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.

EFFECT: there are produced new benzimidazole derivatives showing PPARγ modulatory activity.

41 cl, 2 dwg, 6 tbl, 76 ex

Diuretic // 2456002

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to experimental medicine, namely to pharmacology. The object in view is achieved by the fact that 0.5% humic acids additionally containing magnesium sulphate (II) are applied as a diuretic in the following proportions: 0.5% humic acids - 40 ml; magnesium sulphate - 0.1 g.

EFFECT: higher clinical effectiveness and eliminated side effects.

1 cl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to therapeutically active chemical compounds which influence uriniparous activity of kidney and specifically a peptide which causes selective increase in release of potassium ions by kidneys.

EFFECT: obtaining a compound for treating hyperkalaemia.

1 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to biologically active peptides able to inhibit myosin light chain kinase and thereby regulate the variability of vascular endothelial permeability. What is offered is a cyclic nonapeptide of formula cyclo[-Arg-Lys-Lys-Tyr-Lys-Tyr-Arg-Arg-Lys-].

EFFECT: peptide can find application as a decongestant in various fields of medicine.

2 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery and can be used for treatment of distal postmastectomy lymphedema. For this purpose at the background of standard treatment 6 procedures of retrograde lymphotropic introduction of drug mixture are carried out. Lymphotropic introduction is performed in the following way: in area of middle third of forearm applied is cuff, with creating in it pressure of 60 mm Hg, after which in two points on internal surface in area of wrist introduction of mixture of medications is performed. Composition of introduced mixture alternates every second day: 1, 3, 5 days - actovegin 80 mg, ketonal 1 ml, marcaine 0.5% 4 ml; 2, 4, 6 days - chymotrypsin 100 mg, marcaine 0.5% 4 ml.

EFFECT: method ensures efficient treatment of postmastectomy lymphedema due to enhancing of lymphatic drainage of distal parts of extremity.

3 tbl, 2 ex, 1 dwg

Diuretic // 2408367

FIELD: medicine, pharmaceutics.

SUBSTANCE: there is offered the administration of the preparation Histochrome (echinochrome, 2,3,5,6,8-pentahydroxy-7-ethyl-1,4-nahthochine, formerly known as an antioxidant) as a diuretic.

EFFECT: histochrome exhibits an evident diuretic action equal thiazide-type diuretics in intensity, does not cause associated hypokaliemia, has an absolute advantage over thiazide-type diuretics.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to biologically active peptides, able to prevent sharp increase of permeability of vessel endothelium. Claimed is peptide of formula H-(N-Me)-Arg-Lys-Lys-Tyr-Lys-Tyr-Arg-Arg-Lys-NH2 and its pharmaceutically acceptable salts.

EFFECT: peptide can be applied as anti-edema medication in various fields of medicine.

1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to peptides of general formula , and to their cosmetically or dermopharmaceutically acceptable salts, where: X is chosen from the group formed by cysteinyl, seryl, threonyl and aminobutyryl; R1 is chosen from the group formed by H or a saturated linear C2-C24 acyl group; R2 is chosen from the group formed by an amino group optionally substituted with C1-C24 alkyl, or a hydroxy group. Besides the invention covers a method for making said peptides, their cosmetic or dermopharmaceutical compositions intended for reducing or eliminating baggy lower eyelids.

EFFECT: higher effectiveness.

12 cl, 7 ex

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical compound to improve renal function that contains KW-3902 30 mg or its pharmaceutically acceptable salt, ester, amide, and furosemide. Also there are disclosed method to induce diuretic effect, method to improve renal function, method to support renal function and method to recover renal function in a patient.

EFFECT: effective recovery of renal function in patients with congestive heart failure.

13 cl, 2 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to resuscitation and intensive therapy and can be used in treatment of hemorrhagic shock of I, II and II degree of severity. Method of hemorrhagic shock treatment. For this purpose, assessment of degree of hemorrhagic shock severity is carried out, and in case of hemorrhagic shock of 1 degree of severity in the programme of infusion therapy included are: crystalloid solution of isotopic sterofundin in dose 3000 ml per day and 4% colloidal solution of modified gelatin in volume 1000 ml per day, in case of hemorrhagic shock of II degree of severity - 1200 and 2500 ml respectively, in case of hemorrhagic shock of III degree of severity - 1200 and 3500 ml respectively.

EFFECT: method makes it possible to improve results of treating patients with hemorrhagic shock at pre-hospital and hospital stages due to reduction of risk of electrolyte and acid-alkaline disorders.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present group of inventions refers to medicine, namely to a combined therapy consisting of a dipeptidyl peptidase 4 (DPP4) inhibitor and a sodium glucose co-transporter (SGLT) inhibitor. The combined administration of the DPP4 and SGLT inhibitors of specific chemical structure provides higher blood plasma glucagon-like peptide-1 (GLP-1) due to their synergetic effect.

EFFECT: effect can be used for the effective treatment of diabetes and other diseases and conditions the pathogenesis of which is characterised by an importance of the GLP-1 levels.

15 cl, 6 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, oncology, and may be used for treating the patients with stomach cancer T3-4N1-3M0. Microirrigators are inserted in an abdominal cavity during a surgical intervention. An adjuvant treatment is applied 2-3 weeks later. It involves the endolymphatic introduction of methotrexate. It is followed by a two-week gamma-therapy in accelerated fractionation mode with single radiation dose (SRD) 1.2 Gy twice a day every 5 h. Eloxatine dissolved in ozonised 5% glucose is introduced drop-by-drop in microirrigators with underlying emission on 4th, 8th and 12th day from the beginning between fractionations. In the middle of an arranged pause, the radiation therapy involves single intravenous introduction of etoposide, leucovorin, 5-fluorouracil. The second stage involves the endolymphatic introduction of methotrexate, and 2 days later gamma-therapy is applied once more in the accelerated fractionation mode with SRD 1 Gy twice a day every 5 h with underlying on 32nd, 36th and 40th day from the beginning of treatment, eloxatine dissolved in ozonised 5% glucose is introduced drop-by-drop in microirrigators between fractionations.

EFFECT: method prolongs remission, terminates process generalisation, eliminates recurrences.

2 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to traumatology, and deals with elaboration of problems of treating traumatic affection of joints. Results, carried out in experiment, make it possible to suggest the following method of treating intraarticular fractures. Immobilisation of joint with recovery of anatomically correct interrelationship, stabilisation and further training movements in joint by means of apparatus of external fixation are performed. After recovery of anatomically correct interrelationship, not later than 3 days after trauma, joint surfaces are brought apart for the width which up to 50% exceeds the width of joint space of unaffected joint. During 4-5 days 24-hour drop-by-drop introduction of 0.9% sodium chloride solution into joint cavity is performed. Simultaneously one time per day freshly prepared solution consisting of 40% glucose solution, 5% ascorbic acid solution and autologic blood plasma, taken in volume ratio 1:2:7.

EFFECT: method ensures considerable reduction of fracture treatment terms in comparison with such treated by method of tranosseous osteosynthesis with application of apparatuses of external fixation due to enhancement of reparative regeneration processes.

3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to abdominal surgery and oncology, and may be used for treating patients with tumour intestinal obstruction. The method involves gastrointestinal decompression, active lavage, enterosorption, enteral nutrition. The enteral therapy is intraoperative. The minimum early enteral nutrition is prescribed on the first postoperative day and thereafter; adequate tolerance of the probe nutrition and the presence of minimum excretion allows alternation of various formulae for enteral nutrition. On the first postoperative day, a monomer formula with added 20% Nutriene Elemental 200 ml is introduced. On the second day, Nutriene Elemental is introduced in the volume of 10 kcal/day. On the third day, Nutrisone Standard is introduced in the volume of 15 kcal/day. On the forth day, the formula Nutrisone Energia with dietary fibres is introduced in the volume of 20 kcal/day. On the fifth day, after the nasointestinal probe has been removed and unassisted stool is observed, Pevzner's therapeutic diet No.1 which is added by the introduction of the formula Nutrisone Energia with dietary fibres by sipping method.

EFFECT: method provides clinical effectiveness including ensured by correction of protein-calorie and intestinal insufficiency in the patients with acute intestinal obstruction of tumour aetiology.

1 tbl, 2 ex

FIELD: food industry.

SUBSTANCE: invention relates to a carbohydrate gel for sport alimentation; the gel contains at least water in an amount of 20-60 g/100 g of the gel, glucose and fructose at a ratio of values within the range of 3:1 - 1:1. The gel represents a semi-solid material with a consistence relatively soft and viscous during chewing. The gel is applied in an amount corresponding to consumption of at least 30 g of CHO (carbohydrates) per hour, preferably - at least 50 g of CHO per hour, more preferably -at least 65 g of CHO per hour and most preferably - between 80 g of CHO per hour and 110 g of CHO per hour.

EFFECT: carbohydrate gel may be applied for minimisation of digestive tract related problems in the process of training, for maintaining a higher level of sugar in blood and intensified oxidation of exogenic carbohydrates as well as for preparation of a food product intended to ensure enhanced effectiveness in the process of training and to simultaneously ensure improved digestive acceptability and/or for therapy or prevention of digestive tract related problems.

17 cl, 5 dwg, 2 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly a drug for control of lipid metabolism. A drug in the form of an alcoholic solution for control of lipid metabolism prepared with the use homeopathic technology by multiple serial dilution and external exposure consisting in very-low-dose substances in the activated form which as a substance contains monosaccharides in the form of glucose and/or fructose, and/or galactose, and/or mannose.

EFFECT: drug is effective for control of lipid metabolism; side effects are absent.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine and chemical-pharmaceutical industry, in particular, to medication, applied in case of myocardial infarction and operations on heart in conditions of artificial blood circulation. Water-soluble composition for intravenous introduction, contains ingredients with the following component ratio in wt %: D-glucose 23.40-28.60; potassium chloride 0.14-0.16; potassium salt of L-asparaginic acid 0.81-0.99; semi-magnesium salt of L-asparagenic acid (magnesium L-aspartate) 0.72-0.88; human insulin genetically engineered (in IU/l) 54.00-66.00; dinitrosyl complex of iron (II) with glutathione 0.19-0.23; water for injections - remaining part, with solution pH 7.4±0.1 at 22°C.

EFFECT: application of composition ensures limitation of myocardial infraction size, recovery of metabolic condition of heart at reperfusion, reduces injury of membranes of post-ischemic cardiomyocytes with smaller haemodinamics disorders as compared with traditionally applied medications.

2 dwg, 7 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns a method for making a hemodialysis solution used in extracorporal blood purification for treating patients with acute and chronic renal insufficiency. The hemodialysis solution contains the following components, mmol/l: Sodium chloride NaCl 137.3-140.3; Calcium chloride CaCl2·2H2O 1.2-1.75; Magnesium chloride MgCl2·6H2O 0.5-1.0; Potassium chloride KCl 0.3-4.0; Glucose, g/l 1.0-5.0; Hydrochloric acid 0.1-2.9; Amber acid C4H6O4 0.1-2.9; Sodium bicarbonate 32.0.

EFFECT: invention aims at producing a physiologic composition of an acid component with no acetic acid added, providing minimum complications in the form of acidosis, and haemodynamic stability in patients of a risk group and a cardiac intensive profile.

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, in particular, to field of intestine disbiosis, and can be applied for prevention or within complex therapy. Method of correcting intestinal microflora includes per oral introduction of prebiotic medication, and as prebiotic medication applied is mannose monopreparation in amount 0.01-0.02% to weight of experimental animal bode, and it is introduced in food diet of experimental animals until normal microflora is restored.

EFFECT: claimed method of intestinal microflora correction makes it possible to restore intestinal microflora, excluding risk of allergic reactions development due to application of mannose monopreparation.

1 tbl, 2 ex

FIELD: medicine, neurology.

SUBSTANCE: method involves intravenous administration of autolymphocytes treated with an immunomodulating agent by extracorporal method using cycloferon (250 mg) as an immunomodulating agent. Simultaneously, the following medicinal mixture comprising lidocaine, 100 mg; lidazum, 32 U; dexamethasone, 4 mg; leukinferon, 10 000 U; 40% glucose solution, 4 ml is administrated into interspinal ligaments of spinal column at levels corresponding to thoracal and lumbar enlargements of the spinal cord. The procedure is repeated three times with interval for 48-72 h. Method provides enhancing the effectiveness of lymphostimulation and immunomodulation in cerebrospinal sclerosis. Invention can be used for lymphostimulation and immunomodulation in cerebrospinal sclerosis.

EFFECT: improved method for treatment.

1 tbl, 1 ex